Home > Insider Trading > Filing (0000904454-16-001373)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1377121	Protagonist Therapeutics Inc	PTGX	Pharmaceutical Preparations (2834)	NJ

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
200406	Johnson & Johnson	One Johnson &Amp; Johnson Plaza New Brunswick NJ 08933		No	No	Yes	No
924020	Johnson & Johnson Innovation - Jjdc, Inc.	One Johnson &Amp; Johnson Plaza New Brunswick NJ 08933		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-08-16	965,517	$0.00	965,517	No	4	C	Indirect	By Johnson & Johnson Innovation - JJDC, Inc.
Common Stock	Acquisiton	2016-08-16	900,333	$0.00	1,865,850	No	4	C	Indirect	By Johnson & Johnson Innovation - JJDC, Inc.
Common Stock	Acquisiton	2016-08-16	583,333	$12.00	2,449,183	No	4	P	Indirect	By Johnson & Johnson Innovation - JJDC, Inc.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Johnson & Johnson Innovation - JJDC, Inc.
No	4	C	Indirect	By Johnson & Johnson Innovation - JJDC, Inc.
No	4	P	Indirect	By Johnson & Johnson Innovation - JJDC, Inc.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2016-08-16	14,000,000	$0.00	965,517	$0.00
Common Stock	Series C Preferred Stock	Disposition	2016-08-16	13,054,830	$0.00	900,333	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Each share of the Issuer's Series B Preferred Stock and Series C Preferred Stock automatically converted into the Issuer's Common Stock on a 1-for-14.5 basis at the closing of the Issuer's initial public offering and had no expiration date.
The number of shares of Common Stock reflects a 1-for-14.5 reverse stock split, which became effective on August 1, 2016. Pursuant to the reverse stock split, every 14.5 shares of Series B Preferred Stock and Series C Preferred Stock converted into one share of Common Stock at the closing of the Issuer's initial public offering, for no additional consideration.
The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.